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Retrograde transportRab is a small GTP-binding protein family that regulates various pathways of vesicular transport. Althoughmore
than 60 Rab proteins are targeted to speciﬁc organelles in mammalian cells, the mechanisms underlying the
speciﬁcity of Rab proteins for the respective organelles remain unknown. In this study, we reconstituted the
Golgi targeting of Rab6A in streptolysin O (SLO)-permeabilized HeLa cells in a cytosol-dependent manner and
investigated the biochemical requirements of targeting. Golgi-targeting assays identiﬁed Bicaudal-D (BICD)2,
which is reportedly involved in the dynein-mediated transport of mRNAs during oogenesis and embryogenesis
in Drosophila, as a cytosolic factor for the Golgi targeting of Rab6A in SLO-permeabilized HeLa cells. Subsequent
immunoﬂuorescence analyses indicated decreased amounts of the GTP-bound active form of Rab6 in BICD2-
knockdown cells. In addition, ﬂuorescence recovery after photobleaching (FRAP) analyses revealed that
overexpression of the C-terminal region of BICD2 decreased the exchange rate of GFP–Rab6A between the
Golgi membrane and the cytosol. Collectively, these results indicated that BICD2 facilitates the binding of
Rab6A to the Golgi by stabilizing its GTP-bound form. Moreover, several analyses of vesicular transport
demonstrated that Rab6A and BICD2 play crucial roles in Golgi tubule fusion with the endoplasmic reticulum
(ER) in brefeldin A (BFA)-treated cells, indicating that BICD2 is involved in coat protein I (COPI)-independent
Golgi-to-ER retrograde vesicular transport.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Rab proteins belong to the Ras superfamily of small GTPases. They
comprise the largest branch of the superfamily and more than 60 Rab
proteins have been identiﬁed in mammalian cells [1,2]. Each Rab pro-
tein targets speciﬁc organelles and regulates speciﬁc stages of vesicular
transport. The precise targeting of Rab proteins to speciﬁc organelles is
important for their functions, because it determines the localization of
the corresponding effector proteins [3]. However, the detailed mecha-
nisms underlying Rab targeting remain poorly understood.RAP, ﬂuorescence recovery after
in A; COPI, coat protein I; TGN,
tment;VSVG,vesicularstomati-
ort buffer; Stx, Shiga toxin;CtxB,
nose-6-phosphatereceptor;PM,
nd Sciences, The University of
x: + 81 3 5454 6360.
ata).Previous studies have demonstrated several mechanisms of
Rab targeting. Rab proteins are associated with membranes via
geranylgeranyl groups that are attached to cysteine residue(s) at the
C-terminus [1], and prenylation is reportedly essential for appropriate
localization [4,5]. However, these ﬁndings fail to provide a sufﬁcient
explanation for organelle-speciﬁc targeting, because prenylation is a
common feature of all Rab proteins. Early studies suggested that the
distinct localization is determined by the hypervariable regions at the
C-terminus of Rab proteins [6–8]. However, recently, Ali et al. [9]
showed that the hypervariable region is not a general targeting domain
and identiﬁed other regions that may facilitate speciﬁc localization of
Rab proteins. Guanine nucleotide exchange factor (GEF) is a factor
that activates Rab proteins by catalyzing the exchange of GDP for GTP
[1,10]. Several studies have recently demonstrated that GEFs are
involved in Rab targeting to speciﬁc membranes [11,12].
Rab proteins require various Rab effector proteins to perform their
functions. These effectors usually interact with speciﬁc GTP-bound
Rab proteins and mediate downstream effects. For example, Rab
proteins and their effectors coordinately regulate distinct membrane
transport steps such as budding, movement, tethering, and fusion of
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targeting of Rab to speciﬁc organelles. It has been reported that tail-
interacting protein of 47 kDa (TIP47), one of the effectors of Rab9 (late
endosomal Rab), may play an essential role in the localization of Rab9
[14,15].
Rab6 is localized to medial and trans-Golgi cisternae and to the
trans-Golgi network (TGN) [16,17] and is primarily involved in retro-
grade transport between theGolgi apparatus and the endoplasmic retic-
ulum (ER). At least 2 distinct pathways mediate retrograde transport
from the Golgi to the ER [18,19]. Among these, the coat protein I
(COPI)-dependent pathway is well characterized, involving the trans-
port of ER-resident proteins and some protein toxins with the signal
peptides KDEL or KKXX from the Golgi to the ER via COPI-coated vesi-
cles. In contrast, Rab6 reportedly regulates the COPI-independent path-
way and mediates the transport of proteins and toxins that lack these
amino acid signals [18,20]. To date, 4 isoforms of Rab6 have been iden-
tiﬁed, named Rab6A, Rab6A′, Rab6B, and Rab6C [21]. Both Rab6A and
Rab6A′ are ubiquitously expressed in mammalian cells, whereas
Rab6B is speciﬁcally expressed in the brain [22]. Rab6C is expressed
only in the brain, testis, prostate, and breast [23]. Although Rab6A and
Rab6A′have similar biochemical and genetic properties, they reportedly
play different roles [24,25].
In this study, we developed a system of semi-intact cells to identify
cytosolic protein factors that mediate the targeting of Rab6A to the
Golgi apparatus. Plasma membranes of semi-intact cells were perme-
abilized using bacterial pore-forming toxin streptolysin O (SLO) [26,
27], which binds to cholesterol and oligomerizes to form pores. The cy-
tosolic factors were subsequently released from these pores, whereas
the organelles and cytoskeleton remained almost intact. Various intra-
cellular events can be functionally reconstituted by incubating semi-
intact cells with ATP-regenerating systems and cytosols. These compo-
nents are prepared from cells under various conditions and enable in-
vestigation of factors that are essential to the reconstitution process
following the biochemical addition of cytosol. Using this assay system,
we reconstituted the targeting of recombinant GST-tagged Rab6A
(GST–Rab6A) to the Golgi in semi-intact HeLa cells in a cytosol-
dependent manner. Subsequent pull-down experiments and liquid
chromatography–tandem mass spectrometry (LC–MS/MS) analyses
identiﬁed the cytoplasmic dynein-binding protein Bicaudal-D (BICD)2
as a candidate mediator of Rab6A targeting to the Golgi. Further exper-
iments using semi-intact and intact HeLa cells showed that BICD2 was
responsible for the targeting (especially the binding) of Rab6A to the
Golgi. Finally, analyses of antero- or retrograde vesicular transport
from the Golgi demonstrated signiﬁcantly delayed fusion of brefeldin
A (BFA)-induced Golgi tubules with the ER in BICD2-knockdown cells.
Furthermore, the kinetics of fusion were impaired to a degree similar
to those in Rab6-knockdown cells. These observations indicate that
BICD2 interacts with Rab6A to mediate COPI-independent Golgi-to-ER
retrograde transport.
2. Materials and methods
2.1. Cell culture
HeLa cells were cultured in DMEM (Nissui) supplemented with 10%
fetal bovine serum (FBS; Nichirei Biosciences, Tokyo, Japan) and penicil-
lin/streptomycin (GIBCO).
2.2. Reagents and antibodies
GTP, ATP, creatine phosphate, creatine kinase, and the protease
inhibitors antipain, chymostatin, pepstatin A, and leupeptin were pur-
chased fromSigma.Mouse BICD2 cDNAwas purchased fromDNAFORM.
Nocodazole and Triton X-114 were purchased from Sigma-Aldrich. SLO
was purchased from BioAcademia. All siRNAs were purchased from Ap-
plied Biosystems. The Escherichia coli strain BL21(DE3) was purchasedfrom Invitrogen. Other reagents were purchased fromWako Chemicals.
Primary antibodies included Alexa Fluor 488-conjugated anti-GST
(Invitrogen), rabbit anti-BICD2 (Abcam), rabbit anti-BICD1 (a generous
gift from Dr. Akira Kikuchi, Osaka University, Osaka, Japan, or Abcam),
rabbit anti-Rab6 (Santa Cruz Biotechnology), rabbit anti-Rabkinesin-6
(Bethyl Laboratories, Inc.), rabbit anti-ZW10 (Abcam), rabbit anti-
mannosidase II (Chemicon), rabbit anti-CI-M6PR (IBL), rabbit anti-
EEA1 (BD Transduction Laboratories), rabbit anti-GFP (MBL), mouse
anti-GAPDH (Chemicon), mouse anti-ER–Golgi intermediate compart-
ment (ERGIC)-53 (kindly donated by Dr. Hans-Peter Hauri, University
of Basel, Switzerland), mouse anti-β-tubulin (Sigma-Aldrich), mouse
anti-GM130 (BD Transduction Laboratories), mouse anti-p230 (BD
Transduction Laboratories), mouse anti-calnexin (BD Transduction Lab-
oratories), mouse anti-mCherry (Clontech), mouse anti-mannosidase II
(Abcam), and human anti-Rab6-GTP (AdipoGen International). The fol-
lowing secondary antibodies were used for immunoﬂuorescence: Alexa
Fluor 488-conjugated anti-human antibody (Molecular Probes), Cy2-
conjugated anti-mouse or anti-rabbit antibodies (Chemicon), Cy3-
conjugated anti-mouse or anti-rabbit antibodies (Chemicon), and Cy5-
conjugated anti-mouse antibody (Chemicon). Secondary horseradish
peroxidase (HRP)-conjugated anti-mouse (Promega) or anti-rabbit
(Cell Signaling Technology) antibodies were used in western blotting
experiments.
2.3. Plasmids
The GFP-tagged vesicular stomatitis virus glycoprotein (VSVGts045)
construct was a gift from Dr. Jennifer Lippincott-Schwartz (National In-
stitutes of Health, Bethesda, MD, USA). Human galactosyltransferase
(GT) fused with GFP (GT–GFP)was constructed as described previously
[28]. The GFP–Rab6A construct was a gift from Dr. Hiroyuki Arai (The
University of Tokyo, Tokyo, Japan). The GST-tagged human Rab6A
(GST–Rab6A) construct was generated by subcloning the gene from
the GFP–Rab6A construct into the pGEX-5X-1 vector (GE Healthcare).
Mouse BICD2 was ampliﬁed from BICD2 cDNA (MGC clone 5324113)
using polymerase chain reaction (PCR) and was subcloned into pET-
28b(+) (Novagen), pmCherry-C1 (Clontech), or pEGFP-C1 vectors
(Clontech).
2.4. Plasmid and siRNA transfection
Cells were transfectedwith plasmids using FuGENE HD Transfection
Reagent (Promega) according to the manufacturer's instructions. Vali-
dated or predesigned siRNA oligonucleotides for human BICD2 (siRNA
ID s225943, s23498), BICD1 (siRNA ID s1983, s1984), and Rab6 (siRNA
ID s11685) were purchased from Applied Biosystems. Gene silencing
was achieved by transfecting the cells with 50–100 nM siRNA using
Lipofectamine 2000 (Invitrogen) according to the manufacturer's
instructions.
2.5. Immunoﬂuorescence microscopy
Immunoﬂuorescence staining of intact HeLa cells was performed
using 2 different methods. Staining with Rab6 antibody was performed
according to the method of Young et al. [29] with minor modiﬁcations.
In brief, HeLa cells were grown on coverslips, ﬁxed with 3% paraformal-
dehyde for 20 min, washed 3 times with PBS, and quenched with
50 mM NH4Cl for 15 min. Subsequently, the cells were permeabilized
with PBS containing 0.05% saponin and 0.2% bovine serum albumin
(BSA) for 5 min. The coverslips were then incubated with anti-Rab6
antibody (and other appropriate antibodies) in the same buffer for
1 h, washed twice with PBS, and incubated with the appropriate sec-
ondary antibodies for 1 h. Stainingwith other antibodieswas performed
as described previously [30]. In both methods, the coverslips after the
incubation with the secondary antibodies were washed with PBS,
mounted onmicroscope slides, and analyzed using an LSM510 confocal
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form of Rab6) and Rab6 (total Rab6) in the cells was quantiﬁed by stain-
ing with antibodies against Rab6-GTP (green) and Rab6 (red), and Z-
stack images of the cells were acquired with a slice thickness of 1 μm.
The images were then superimposed, and the ﬂuorescence intensities
of entire regions of each cell weremeasured using pixel ﬂuorescence in-
tensities. Theﬂuorescence intensities of other regionsweremeasured as
background and the ratios of the ﬂuorescence intensity of Rab6-GTP
(green) to the ﬂuorescence intensity of Rab6 (red) were calculated for
each cell. Finally, the mean ratios of the ﬂuorescence intensities in
BICD1- and/or BICD2-knockdown cells were normalized to that in con-
trol (scramble siRNA) cells. BICD1 and/or BICD2 siRNA conditions were
compared with the control (scramble) siRNA condition using Steel's
test.
2.6. Preparation of L5178Y cytosol
L5178Y cytosol was prepared from L5178Y cells according to pre-
viously described methods [28].
2.7. Golgi-targeting assay
Semi-intact HeLa cells were prepared as described previously [28]
with minor modiﬁcations. In brief, HeLa cells were grown on coverslips,
washed twice with ice-cold PBS, and treated with 0.20-μg/ml SLO for
5 min at 4 °C. After washing away excess SLO with ice-cold PBS, the
cells were incubated with prewarmed transport buffer [TB; 25 mM
HEPES-KOH (pH 7.4), 115 mM potassium acetate, 2.5 mM MgCl2, and
2 mM EGTA] for 5 min at 32 °C to induce pore formation in plasma
membranes. The permeabilized cells were washed twice with ice-cold
TB and incubated in TB at 4 °C for 10 min to elute the residual cytosol.
After washing twice with ice-cold TB, the cells were incubated with
5 μg of GST–Rab6A, an ATP-regenerating system (1 mM ATP, 50 μg/ml
creatine kinase, and 2.62 mg/ml creatine phosphate), 1 mg/ml glucose,
1mMGTP, and either 3mg/ml of cytosol or TB at 32 °C. After incubation
at 32 °C, the cells were subjected to immunoﬂuorescence staining as
described previously [30] with slight modiﬁcations. In brief, the cells
were washed with ice-cold TB before ﬁxation; after blocking, the cells
were incubated with Alexa Fluor 488-conjugated anti-GST antibody in
blocking buffer for 2–3 h instead of the 2-step staining method. Unless
otherwise stated, all procedures were performed at room temperature.
To quantify the ﬂuorescence intensity of GST–Rab6A in the Golgi, we
initially acquired Z-stack images of Alexa Fluor 488-stained cells with
a slice thickness of 1 μm. Subsequently, the images were superimposed
and the ﬂuorescence intensity in the Golgi was determined. The Golgi
region was deﬁned using the trans-Golgi and TGN marker p230, and
we measured the ﬂuorescence intensity of GST–Rab6A in the region
where GST–Rab6A (green) and p230 (red) were colocalized. The ﬂuo-
rescence intensity in other cytoplasmic regions was determined to esti-
mate the background. The mean ﬂuorescence intensity under Cytosol
(−) conditions was arbitrarily assigned as 1.
2.8. Subcellular fractionation
Subcellular fractionation was performed as described previously [31]
with minor modiﬁcations. In brief, conﬂuent HeLa cells were washed
twice with ice-cold PBS; thereafter, the cells were scraped in fraction-
ation buffer [10 mM Tris–HCl (pH 7.4), 0.25 M sucrose, 1 mM MgCl2,
and 5 mM CaCl2], supplemented with protease inhibitors (5 μg/ml
antipain, chymostatin, pepstatin A, and leupeptin) on ice, and homoge-
nized by passing 50 times through a 27-G needle. Post-nuclear superna-
tantswere obtained by centrifuging homogenates at 600×g for 10min at
4 °C. The supernatants were further centrifuged at 100,000 ×g for 1 h
using an Optima TLX ultracentrifuge (Beckman) and a TLA100.3 rotor
to generate cytosol fractions (supernatant) and crude membrane frac-
tions (pellet). The membrane pellets were carefully resuspended incytosolic volumes of fractionation buffer. The cytosol and membrane
fractions were then added to SDS sample buffer and boiled for 5 min at
100 °C. Equal volumes of each fraction were analyzed using western
blotting.
2.9. Preparation of recombinant proteins
The E. coli strain BL21 was transformed with the expression vector
pGEX-5X-1 alone (GST) or with the same vector containing the
human Rab6A gene (GST–Rab6A). The E. coli strain BL21 (DE3) was
transformed with the expression vector pET-28b(+) containing the
mouse BICD2 gene (His-mBICD2). Cells were grown at 37 °C to an
OD600 of 0.5–0.7 in LB medium (for GST–Rab6A and GST) or 2× YTme-
dium containing 0.5%–1% glucose (for His-mBICD2) in the presence of
appropriate antibiotics and were induced using 0.5 mM isopropyl-β-D-
thiogalactopyranoside for 3 h at 30 °C (for GST–Rab6A and GST) or for
5 h at 25 °C (for His-mBICD2). The cells were harvested at 6,000 ×g
for 5 min and resuspended in sonication buffer [50 mM Tris–HCl
(pH 8.0), 50 mM NaCl, 1 mM EDTA-NaOH (pH 8.0), and 1 mM DTT
(for GST–Rab6A and GST) or 50 mM NaH2PO4, 300 mM NaCl, and
10mM imidazole (for His-mBICD2)] containing protease inhibitor cock-
tail (Roche). The resuspended cells were disrupted by sonication, incu-
bated in the presence of 1% Triton X-100 for 30 min, and then
centrifuged at 15,000 rpm for 20 min. Subsequently, the supernatants
were mixed with either Glutathione Sepharose 4B (GE Healthcare; for
GST–Rab6A and GST) or Ni-NTA agarose (QIAGEN; for His-mBICD2)
and incubated for 1–2 h. After incubation, the mixtures were centri-
fuged, washed 4 times with sonication buffer (for GST–Rab6A and
GST) or 50 mM NaH2PO4, 300 mM NaCl, and 20 mM imidazole (for
His-mBICD2), and added to chromatography columns (Bio-Rad). Pro-
teins were then eluted with protease inhibitor cocktail and either a so-
lution containing 10 mM glutathione and 50 mM Tris–HCl (pH 8.0; for
GST–Rab6A and GST) or a solution containing 50 mM NaH2PO4,
300 mM NaCl, and 250 mM imidazole (for His-mBICD2). Afﬁnity-
puriﬁed proteins were concentrated using Microcon centrifugal ﬁlter
devices (Millipore), frozen in liquid nitrogen, and stored at−80 °C. Pro-
tein concentrations were measured using a protein assay kit (Bio-Rad).
Unless otherwise stated, all procedures were performed at 4 °C.
2.10. GST pull-down assay
GST–Rab6A, GST, and L5178Y cytosol were obtained as described
above, and GST pull-down assays were performed using 2methods. Ini-
tially, to remove GST–Rab6A-binding proteins (or GST-binding proteins
as a control) from L5178Y cytosols, GST–Rab6A (or GST as a control)
was incubated with an ATP-regenerating system, 1 mg/ml glucose,
1mMGTP, and 3mg/ml of L5178Y cytosol for 30min at 4 °C. After incu-
bation, the mixtures were incubated in the presence of Glutathione
Sepharose 4B beads for 2 h at 4 °C and then centrifuged at 15,000 rpm
for 5 min at 4 °C. The supernatants were then incubated with new
beads for 2 h at 4 °C and centrifuged at 15,000 rpm for 5 min at 4 °C
(this stepwas repeated twice). Subsequently, themixtures were centri-
fuged and the supernatants containing Cytosol (−RBP) or Cytosol
(−GST, as a control) were ﬁltered using 0.22-μm ﬁlters (Millipore) to
remove the beads completely. The ﬁltered supernatants were then sub-
jected to theGolgi-targeting assay. If not used immediately, the samples
were frozen in liquid nitrogen and stored at−80 °C. To separate GST–
Rab6A-binding proteins from L5178Y cytosols, GST–Rab6A (or GST as
a control) was incubated with TB and Glutathione Sepharose 4B beads
for 1 h at 4 °C. The mixtures were then centrifuged at 15,000 rpm for
2 min at 4 °C and the supernatants were discarded. The pellets were
washed 4 timeswith TB and then incubatedwith 3mg/ml L5178Y cyto-
sol for 90 min at 4 °C. After incubation, the mixture was centrifuged at
15,000 rpm for 2 min at 4 °C and the supernatant was discarded. The
pellets [GST–Rab6A (or GST) bead fractions] were washed 4 times
with TB and then boiled in SDS sample buffer for 5 min at 100 °C to
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teins were then separated using SDS-PAGE and were stained with
SYPRO Ruby protein stain (Invitrogen). LC–MS/MS was performed by
APRO Life Science Institute, Inc., Tokushima, Japan.
2.11. Immunoprecipitation
HeLa cells were cotransfected with GFP–Rab6A and either an
mCherry-tagged C-terminal fragment of mouse BICD2 (mCherry–
BICD2706–810) or an mCherry-tagged truncated mutant of mouse
BICD2 lacking the C-terminal region (mCherry–BICD21–705). After
24 h, the cells were lysed and subjected to immunoprecipitation as
described previously [32]. The samples were immunoprecipitated
with either anti-GFP antibody or control rabbit IgG and protein G-
Sepharose beads (GE Healthcare).
2.12. Western blotting
The proteins in HeLa cell lysates, subcellular fractionations, bead
fractions, and puriﬁed protein samples were separated using SDS-
PAGE with 12.5% or 5%–20% polyacrylamide gels and transferred to ni-
trocellulose (Bio-Rad) or PVDF membranes (Millipore) using semi-dry
electroblotting. The membranes were blocked using TBS containing 5%
skimmilk (blockingbuffer) and incubatedwith the appropriate primary
antibodies diluted in blocking buffer or Can Get Signal solution I
(Toyobo) for 2 h at room temperature or overnight at 4 °C. After wash-
ing 3 times with TBS or TBST for 5 min, themembranes were incubated
with HRP-conjugated secondary antibodies diluted in blocking buffer or
Can Get Signal solution II (Toyobo) for 1 h at room temperature. Subse-
quently, the membranes were washed 3 times with TBS or TBST for
5 min and protein bands were visualized using Western Lightning
Plus-ECL (PerkinElmer) and LAS-4000mini (Fujiﬁlm). The obtained im-
ages were quantiﬁed usingMulti Gauge version 3.2 software (Fujiﬁlm).
2.13. Nocodazole treatment of semi-intact cells
Semi-intact HeLa cells were treated with nocodazole as described
previously [28] with minor modiﬁcations. HeLa cells were grown on
coverslips, placed on ice for 20 min, and then incubated in the culture
medium containing 2 μg/ml nocodazole for 30 min on ice. The cells
were subsequently incubated at 37 °C for 20 min. After incubation, the
cells were permeabilized with SLO, washed, and incubated with GST–
Rab6A, an ATP-regenerating system, glucose, GTP, 3 mg/ml L5178Y
cytosol, and 1 μg/ml nocodazole at 32 °C for 30 min. The cells were
then ﬁxed and subjected to immunoﬂuorescence staining using Alexa
Fluor 488-conjugated anti-GST antibody and the antibodies described
below. Depolymerization of microtubules in the cells was detected
using anti-β-tubulin antibody, and the Golgi was visualized using anti-
p230 antibody.
2.14. Retrograde transport assay (BFA treatment)
Retrograde transport assayswere performed as described previously
[33–36].
2.15. Fluorescence recovery after photobleaching (FRAP)
HeLa cellswere grownon 35-mmglass-bottomed culture dishes and
cotransfected with plasmids encoding GFP–Rab6A and either mCherry-
tagged truncated BICD2 (BICD2706–810, BICD21–705) or empty mCherry
vector. At 24 h after transfection, time-lapse imaging was performed
using an LSM 510 confocal microscope (Carl Zeiss) with a 63× oil im-
mersion objective. Regions of interest (ROIs) were bleached at 100%
laser power (488 nm laser line). Images were acquired at 10-s intervals
with a low laser power (3%) using a pinhole of 7 μm. Image sequenceswere processed and the ﬂuorescence intensities at perinuclear regions
were quantiﬁed using LSM 510 software.
3. Results
3.1. Targeting of Rab6A to the Golgi apparatus in a cytosol-dependent
manner in semi-intact HeLa cells
To identify the factors that mediate the targeting of Rab6A to the
Golgi apparatus, we established a Golgi-targeting assay using a semi-
intact cell system and a recombinant Rab6A protein as shown in
Fig. 1A. Initially, we prepared and puriﬁed recombinant human Rab6A
with a GST fusion protein (referred to as GST–Rab6A) from E. coli and
prepared cytosols from L5178Y cells as described in Materials and
methods. CBB staining and western blotting experiments conﬁrmed
that the main single band corresponded to GST–Rab6A (Fig. 1B).
Golgi-targeting assays were then performed using the recombinant
protein and cytosols. In these experiments, semi-intact HeLa cells
were incubated with GST–Rab6A and an ATP-regenerating system in
the presence or absence of L5178Y cytosol (3 mg/ml) at 32 °C for
30 min and then subjected to direct immunoﬂuorescence staining
using Alexa Fluor 488-conjugated anti-GST antibody. In the absence of
cytosol, faint ﬂuorescence signals were detected in the perinuclear re-
gions of semi-intact HeLa cells (Fig. 1C and D), whereas in the presence
of the cytosol, extensive ﬂuorescence signals of GST–Rab6Awere clearly
observed in similar cell regions (Fig. 1C and D). Double immunoﬂuores-
cence staining experiments using Alexa Fluor 488-conjugated anti-GST
antibody and antibodies against various organelle markers revealed
that GST–Rab6Awas extensively colocalizedwith the trans-Golgi cister-
nae and TGN marker p230, whereas only partial colocalization was ob-
served between GST–Rab6A and either the ERGIC marker ERGIC-53 or
the cis-Golgi marker GM130 (Fig. 1E). We failed to detect colocalization
of GST–Rab6A with the medial Golgi marker mannosidase II because of
the lack of an anti-GST antibody that operates under the same ﬁxa-
tion conditions as the anti-mannosidase II antibody (Supplementary
Fig. 1A) and vice versa (Supplementary Fig. 1B). Moreover, no colo-
calization of GST–Rab6A with the early endosome marker EEA1 was
observed, indicating cytosol-dependent targeting of GST–Rab6A to the
trans-Golgi and the TGN in semi-intact HeLa cells. Localizations of
GST–Rab6A in semi-intact cells were indistinguishable from those in
intact HeLa cells [16,31,37].
Rab proteins must be prenylated for insertion into membranes
[38–40], and prenylation is reportedly essential for appropriate localiza-
tion [4,5]. Therefore, we next performed Triton X-114 phase parti-
tioning to examine whether GST–Rab6A was prenylated in the Golgi-
targeting assay in the presence of L5178Y cytosol. In brief, semi-intact
HeLa cells were incubated with GST–Rab6A and an ATP-regenerating
system in the presence of L5178Y cytosol. After incubation at 32 °C for
30 min, the cells were lysed and subjected to Triton X-114 phase
partitioning. As shown in Supplementary Fig. 2A, a portion of GST–
Rab6Awas found in the detergent phase.We also found that incubation
with cytosol was sufﬁcient to induce the partitioning of GST–Rab6A to
the detergent phase (Supplementary Fig. 2B). Taken together, these re-
sults indicate that a portion of GST–Rab6A was prenylated during incu-
bation with L5178Y cytosol at 32 °C for 30 min in the Golgi-targeting
assay.
In the absence of the cytosol, faint but substantial ﬂuorescence sig-
nals of GST–Rab6Awere detected at the Golgi (Fig. 1C and D), indicating
that factor(s) involved in the Golgi targeting of GST–Rab6A possibly still
remained in semi-intact cells. The cells werewashedwith TB containing
0.5 M KCl to remove peripheral membrane proteins from the Golgi and
were then subjected to the Golgi-targeting assay. In these experiments,
the extent of the Golgi-targeting of GST–Rab6A was reduced (1.18 ±
0.03) comparedwith the unwashed control (1.63± 0.05) (Fig. 1F), sug-
gesting that cytosolic factors and/or peripheral membrane proteins
coordinately or independently contribute to the targeting of Rab6A.
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2596 M. Matsuto et al. / Biochimica et Biophysica Acta 1853 (2015) 2592–2609The Golgi targeting of GST–Rab6A was also proportional to cytosol
concentrations and incubation times in semi-intact cells incubated
with the cytosol containing GST–Rab6A. Golgi-targeting assays were
performed in semi-intact HeLa cells after incubating with GST–Rab6A
and an ATP-regenerating system in the presence of L5178Y cytosol atprotein concentrations of 0–3 mg/ml. In these experiments, the extent
of targeting increased with increasing concentrations of the cytosol
(Supplementary Fig. 3). Because the maximum concentration of the cy-
tosol was approximately 4 mg/ml, we added the cytosol at a constant
concentration of 3 mg/ml in subsequent assays.
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2597M. Matsuto et al. / Biochimica et Biophysica Acta 1853 (2015) 2592–2609To investigate the optimal incubation time for the assay, semi-intact
HeLa cells were incubated with GST–Rab6A and an ATP-regenerating
system in the presence of 3 mg/ml L5178Y cytosol at 32 °C for
0–70 min, and Golgi-targeting assays were performed. These experi-
ments indicated that incubation for 30 min was sufﬁcient for the Golgi
targeting of GST–Rab6A (Fig. 1G). Hence, the standard Golgi-targeting
assay conditions comprised 3 mg/ml L5178Y cytosol and incubation
for 30 min at 32 °C.
3.2. Independence of the Golgi targeting of GST–Rab6A from the
integrity of microtubules
Rab6A is reportedly involved in microtubule-dependent vesicle
transport [29,41]. Thus, transport vesicles that are involved inanterograde or retrograde transport to the Golgi may transport sub-
stantial amounts of GST–Rab6A to the Golgi. Accordingly, increased
GST–Rab6A in the Golgi may reﬂect vesicular transport rather than
targeting. To eliminate this possibility, we investigated the effect of
microtubules on the targeting of GST–Rab6A by treating HeLa cells
with the microtubule polymerization inhibitor nocodazole, without
signiﬁcant effects on the morphology of the Golgi [28,42]. Sub-
sequently, semi-intact HeLa cells were subjected to the Golgi-
targeting assay in the presence of cytosol containing nocodazole. In
these experiments, GST–Rab6A was equally targeted to the Golgi in
nocodazole-treated and -untreated cells (Fig. 2A and B), indicating
that the observed GST–Rab6A targeting to the Golgi is independent
of microtubule mediated vesicular transport in semi-intact HeLa
cells under these experimental conditions.
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Rab6A to the Golgi
Because GST–Rab6A was targeted to the Golgi in a cytosol-
dependent manner in semi-intact HeLa cells, factors that regulate the
targeting of GST–Rab6A in semi-intact cells were identiﬁed from the
added cytosol fractions. Cytosol (−RBP) was prepared by incubating
L5178Y cytosol with GST–Rab6A and then performing GST pull-down
experiments using Glutathione Sepharose 4B beads to remove GST–
Rab6A-binding proteins. Cytosol (−GST) was prepared as a control
by incubating the cytosol with only GST/glutathione beads (Fig. 3A).
As shown in Fig. 3A, the resulting pellets (bead fraction) should contain
GST–Rab6A and its binding proteins (or GST and its binding proteins
as a control), which should be absent in supernatants. Subsequent
western blotting experiments conﬁrmed that almost all GST–Rab6A
(or GST) was removed from both cytosol preparations (Supplementary
Fig. 4E).
The effects of Cytosol (−RBP) or Cytosol (−GST) on the observed
Rab6A targetingwere assessed in Golgi-targeting assays. In these exper-
iments, the targeting of GST–Rab6Awas reduced (1.39± 0.04) in semi-
intact cells incubated with Cytosol (−GST) compared with that in cells
incubated with cytosol that had not been preincubated with GST [Cyto-
sol (+); 1.52 ± 0.01; Fig. 3B and C]. This reduction may reﬂect the loss
of activity of Cytosol (−GST) following sustained incubation at 4 °C
during the GST pull-down procedure. In contrast, the targeting of
GST–Rab6A was signiﬁcantly reduced (1.08 ± 0.05) in cells incubated
with Cytosol (−RBP), compared with those incubated with Cytosol
(−GST) (P b 0.001, Tukey–Kramer test). Taken together, these data
indicate that Rab6A-binding proteins that coprecipitated with GST–
Rab6A/glutathione beads mediate the targeting of Rab6A to the Golgi
in semi-intact cells.In subsequent experiments, we investigated binding proteins from
the GST–Rab6A/glutathione bead fraction to identify the factors that
may mediate the targeting of Rab6A. The GST–Rab6A bead fraction (or
GST bead fraction as a control) was boiled in SDS sample buffer to
elute GST–Rab6A (or GST as a control)-binding proteins (see Fig. 3A).
These eluted proteins were separated by SDS-PAGE and stained with
SYPRO Ruby protein stain. A protein of approximately 100 kDawas spe-
ciﬁcally detected in the GST–Rab6A bead fraction (Supplementary
Fig. 4A), and excision and LC–MS/MS analysis identiﬁed the band as
BICD2. This 100-kDa band was also detected by western blotting using
anti-BICD2 antibody (Supplementary Fig. 4B), which conﬁrmed re-
duced BICD2 in Cytosol (−RBP) compared with that in Cytosol
(−GST) (Supplementary Fig. 4C). These data indicate that cytosolic
factors interact with Rab6A and mediate the targeting of GST–Rab6A
to the Golgi in semi-intact HeLa cells and that the cytosolic protein
BICD2 is a potential candidate.
3.4. Decreased membrane-bound Rab6 in BICD2-knockdown HeLa cells
RNA interference (RNAi) experimentswere used to examinewheth-
er BICD2 was involved in the localization of endogenous Rab6 in intact
HeLa cells. To minimize off-target effects of siRNAs, we used 2 different
siRNAs against BICD2 (BICD2 siRNA #1, BICD2 siRNA #2). To determine
knockdown efﬁciency, HeLa cells were transfected with BICD2 siRNA
#1, BICD2 siRNA #2, or scramble siRNA as a control; after 72 h, the
cells were harvested, lysed, and subjected to western blotting with
anti-BICD2 antibody. The expression of BICD2 in BICD2 siRNA-
transfected cells was reduced to approximately 20%–30% of that in the
control (28.91% ± 7.83% for BICD2 siRNA #1-transfected cells and
24.02% ± 5.22% for BICD2 siRNA #2-transfected cells; Fig. 4A). Because
Rab6 isoforms are highly similar in HeLa cells (only Rab6A and Rab6A′
0.0  
0.5  
1.0  
1.5  
2.0  
flu
or
es
ce
nc
e 
in
te
ns
ity
 a
t t
he
 G
ol
gi
 
GST
Cytosol (+) Cytosol ( ) Cytosol ( GST) Cytosol ( RBP)B
A
Sup 
Cytosol ( RBP) GST Rab6A
beads
Sup 
Cytosol ( GST) 
GST bead fraction 
including GST- 
binding proteins 
incubate 
beads
GST (control)
GST–Rab6A
centrifuge 
incubate 
centrifuge 
GST-binding proteins 
GST–Rab6A-binding proteins cytosol
cytosol
GST–Rab6A bead 
fraction
including GST–Rab6A- 
binding proteins 
Golgi-targeting 
assay
SYPRO Ruby stain  
LC–MS/MS 
Western blotting
C
Cytosol
(+)
Cytosol
( GST) 
Cytosol
( RBP) 
***
**
Cytosol
( ) 
***
Fig. 3. Targeting of GST–Rab6A to the Golgi was inhibited in the presence of the cytosol lacking Rab6A-binding proteins in semi-intact HeLa cells. A. Experimental outline of the GST pull-
down assay. GST–Rab6A (or GST as a control)was incubatedwith 3mg/ml of L5178Y cytosol at 4 °C in the presence of Glutathione Sepharose 4B beads, and themixtureswere centrifuged.
The resulting pellets (bead fraction) contained themajority of GST–Rab6A (orGST as a control) and its binding proteins. The supernatants [Cytosol (−RBP) or Cytosol (−GST) as a control]
were analyzed using the Golgi-targeting assay to investigate the effect of the depletion of Rab6A-binding proteins on the targeting of GST–Rab6A in semi-intact HeLa cells. Bead fractions
(GST–Rab6A bead fraction or GST bead fractions as a control)were then separated using SDS-PAGE and analyzed using either SYPRORuby protein stain and LC–MS/MS orwestern blotting
to detect and identify potential factors thatmay regulate the targeting ofGST–Rab6A (Supplementary Fig. 4A andB). B. Analysis of Rab6A-binding protein-depleted cytosol using theGolgi-
targeting assay. Semi-intact HeLa cellswere incubatedwith GST–Rab6A, anATP-regenerating system, glucose, andGTP in the presence of the cytosol inwhich the binding proteins of GST–
Rab6A [Cytosol (−RBP)] or GST [Cytosol (−GST), as a control] were depleted. After incubation at 32 °C for 30min, the cells were subjected to the Golgi-targeting assay; the panels show
the representative images of each condition. Bars: 20 μm. C. The graph shows the mean ﬂuorescence intensity of GST–Rab6A at the Golgi in (B). The mean ﬂuorescence intensity of GST–
Rab6A at the Golgi in Cytosol (−) condition was arbitrarily assigned as 1. Data are presented as means and standard deviations of 3 independent experiments (n = 17–31 cells).
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2599M. Matsuto et al. / Biochimica et Biophysica Acta 1853 (2015) 2592–2609[22,23]) and differ by only 3 amino acids [43], no speciﬁc anti-Rab6A-
speciﬁc antibody was available for immunoﬂuorescence staining or
western blotting. Hence, we used an anti-Rab6 antibody that detects
both Rab6A and Rab6A′ for experiments in intact HeLa cells. In theseexperiments, the expression of Rab6 protein was not affected by
BICD2 knockdown (Fig. 4A). Thus, immunoﬂuorescence microscopy
experiments were performed to investigate subcellular localization of
endogenous Rab6 in BICD2-knockdown HeLa cells. In brief, HeLa cells
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2600 M. Matsuto et al. / Biochimica et Biophysica Acta 1853 (2015) 2592–2609were transfected with each BICD2 siRNA or scramble siRNA; after 72 h,
the cells were ﬁxed and double-stained with antibodies against Rab6
and p230. AlthoughGolgi-associated Rab6 signalswere not signiﬁcantlyaltered, the amount of cytoplasmic Rab6 was substantially increased in
BICD2-knockdown cells (Fig. 4B). Therefore, we quantiﬁed the ﬂuores-
cence intensity of Rab6 in the Golgi region (p230 was used as the
0.0  
0.5  
1.0  
1.5  
2.0  
flu
or
es
ce
nc
e 
in
te
ns
ity
 a
t t
he
 G
ol
gi
 
0.0  
0.5  
1.0  
1.5  
2.0  
flu
or
es
ce
nc
e 
in
te
ns
ity
 a
t t
he
 G
ol
gi
 
0.0  
0.5  
1.0  
1.5  
2.0  
flu
or
es
ce
nc
e 
in
te
ns
ity
 a
t t
he
 G
ol
gi
 
0.0  
0.5  
1.0  
1.5  
2.0  
flu
or
es
ce
nc
e 
in
te
ns
ity
 a
t t
he
 G
ol
gi
 
0.0  
0.5  
1.0  
1.5  
2.0  
flu
or
es
ce
nc
e 
in
te
ns
ity
 a
t t
he
 G
ol
gi
 
*****
Cytosol ( ) IgG BICD2 IgG BICD2
2 µg 5 µg
Cytosol
( RBP) 
Cytosol (+) Cytosol
( RBP) 
+BICD2
*
Cytosol ( ) IgG BICD1 IgG BICD1
1 µg 2 µg
A B
E
C D
Cytosol ( ) IgG Rabkinesin IgG Rabkinesin
1 µg 2 µg
Cytosol ( ) IgG ZW10 IgG ZW10
2 µg 5 µg
**
***
***
N.S. N.S.***
***
N.S. N.S.***
***
N.S. N.S.**
***
Fig. 5.Restoration of Cytosol (−RBP)-inhibitedGST–Rab6A targeting byHis-mBICD2 in semi-intactHeLa cells. A. Targeting of GST–Rab6A to theGolgiwas inhibited by the addition of anti-
BICD2 antibody in semi-intact HeLa cells. Semi-intact HeLa cellswere incubated at 32 °C for 30minwith 2 or 5 μg of control rabbit IgG (IgG) or anti-BICD2 antibody (BICD2) in the presence
of GST–Rab6A, an ATP-regenerating system, glucose, GTP, and 3mg/ml of HeLa S3 cytosol and were subjected to the Golgi-targeting assay. The graph shows themean ﬂuorescence inten-
sity of GST–Rab6A at the Golgi. The mean ﬂuorescence intensity in the Cytosol (−) condition was arbitrarily assigned as 1. Data are presented as means and standard deviations of 3
independent experiments (n = 27–34 cells per experiment); ***P b 0.001, **P b 0.01 (Tukey–Kramer test). B. Targeting of GST–Rab6A to the Golgi was not inhibited by the addition of
anti-BICD1 antibody in semi-intact HeLa cells. Semi-intact HeLa cells were incubated at 32 °C for 30 min with 1 or 2 μg of control rabbit IgG (IgG) or anti-BICD1 antibody (BICD1) in
the presence of GST–Rab6A, an ATP-regenerating system, glucose, GTP, and 3 mg/ml of HeLa S3 cytosol and were subjected to the Golgi-targeting assay. The graph shows the mean
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ﬂuorescence intensity in the Cytosol (−) condition was arbitrarily assigned as 1. Data are presented as means and standard deviations of 3 independent experiments (n = 26–34 cells
per experiment); **P b 0.01, ***P b 0.001, N.S.P N 0.05 (Tukey–Kramer test). E. Semi-intact HeLa cells were incubated at 32 °C for 30 min with GST–Rab6A, an ATP-regenerating system,
glucose, GTP, and Cytosol (−RBP) in the presence or absence of 10 μg of His-mBICD2 and were subjected to the Golgi-targeting assay. The mean ﬂuorescence intensity in the Cytosol
(−RBP) condition was arbitrarily assigned as 1. Data are presented as means and standard deviations of 3 independent experiments (n = 26–32 cells per experiment). *P b 0.05,
**P b 0.01; Dunnett's test.
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2603M. Matsuto et al. / Biochimica et Biophysica Acta 1853 (2015) 2592–2609Golgimarker). Our results showed that BICD2 depletion decreased Rab6
signal in the Golgi region (compared with other cytoplasmic regions)
(Fig. 4C). These data indicate that BICD2 knockdown reduced the bind-
ing of Rab6 to the Golgi.
In subsequent subcellular fractionation experiments,we determined
whether BICD2 knockdown decreased membrane-bound Rab6. BICD2
or scramble siRNA-transfected cells were harvested, homogenized,
and centrifuged to separate the membrane (mb) and cytosol (cyt) frac-
tions. The fractions were then analyzed by western blotting using anti-
Rab6 antibody, and the ratio of Rab6 in the cytosol fractionswas slightly
but substantially increased BICD2 siRNA #1-transfected cells (1.085 ±
0.086) and BICD2 siRNA #2-transfected cells (1.135 ± 0.091) relative
to that in control cells (considered to be 1). In contrast, Rab6 ratios in
the membrane fractions were decreased to 0.927 ± 0.043 in BICD2
siRNA #1-transfected cells and 0.880 ± 0.038 in BICD2 siRNA #2-
transfected cells relative to that in control cells (Fig. 4D and E).
The mammalian BICD homologues BICD1 and BICD2 are highly
homologous and reportedly compensate for each other's function
[44–48]. Therefore, we performed subcellular fractionation of BICD1-
knockdown and BICD1/BICD2 double-knockdown cells to examine the
localization of Rab6. In these experiments, the ratio of Rab6 in the cyto-
sol fraction was increased to 1.138 ± 0.090 relative to control cells and
that in the membrane fraction was decreased to 0.878 ± 0.073 com-
pared with control cells (considered to be 1) in BICD1/BICD2 double-
knockdown cells, similar to that in BICD2-knockdown cells (Supple-
mentary Fig. 6A and B). In contrast, this ratio was not altered in
BICD1-knockdown cells (Supplementary Fig. 6C and D). We also con-
ﬁrmed that Rab6 protein expression was not affected by BICD1/BICD2
double-knockdown (99.78% ± 8.97% relative to control cells) or BICD1
knockdown (101.51% ± 10.21% for BICD1 siRNA #1-transfected cells
and 101.53% ± 13.01% for BICD1 siRNA #2-transfected cells relative to
control cells; Supplementary Fig. 6E and F). Taken together, these
results indicate that BICD2 is involved in the localization of Rab6 to
the Golgi membranes in intact HeLa cells.
3.5. Restoration of Rab6A targeting to the Golgi by addition of BICD2 in
semi-intact HeLa cells
As shown in Fig. 4, BICD2 knockdown affected the localization of en-
dogenous Rab6 in intact HeLa cells. However, this effect was relatively
small and Rab6A and Rab6A′ were not detected separately because of
the lack of a speciﬁc antibody for Rab6A. Therefore, we performed the
Golgi-targeting assay in the presence of cytosol containing anti-BICD1
or 2 antibody. Because the present anti-BICD2 antibody recognizes
only human BICD2, Golgi-targeting assays were performed with the cy-
tosols from HeLa S3 cells instead of mouse L5178Y cells. In brief, semi-
intact HeLa cells were incubated at 32 °C for 30 min with control rabbit
IgG, anti-BICD2, or anti-BICD1 antibody in the presence of GST–Rab6A,
an ATP-regenerating system, and 3 mg/ml HeLa S3 cytosol. In subse-
quent Golgi-targeting assays (Fig. 5A and B), anti-BICD2 antibody
inhibited the targeting of GST–Rab6A to the Golgi, whereas anti-BICD1
antibody did not.
We also performed theGolgi-targeting assay in the presence of cyto-
sol containing anti-Rabkinesin-6 antibody because Rabkinesin-6 (also
known as KIF20A/RAB6KIFL/MKlp2) is a known effector of Rab6A [43,
49]. Semi-intact HeLa cells were incubated at 32 °C for 30 min withFig. 6. Signiﬁcant impairment of GFP–Rab6A dynamics in HeLa cells overexpressing the C-term
BICD2706–810 and BICD21–705. Three coiled-coil regions are indicated as CC1, 2, and 3 (white b
(mCherry–BICD2706–810) or mCherry-tagged BICD21–705 (mCherry–BICD21–705). HeLa cells we
or mCherry–BICD21–705, and immunoprecipitation (IP) was performed using anti-GFP antibod
with anti-GFP and anti-mCherry antibodies. This ﬁgure is representative of 3 independent ex
mCherry-tagged truncated form of BICD2. HeLa cells were cotransfected with plasmids encodin
as a control (mock) and were ﬁxed and stained with antibody against p230. Bars: 20 μm. D.
expressing the truncated form of BICD2. HeLa cells were cotransfected with GFP–Rab6A an
(mock). The cells were analyzed using FRAP at 24 h after transfection. The left panels show
representative of 3 independent experiments. The graph are presented as means and standardcontrol rabbit IgG or anti-Rabkinesin-6 antibody in the presence of
GST–Rab6A, an ATP-regenerating system, and 3mg/ml HeLa S3 cytosol.
In this experiment, anti-Rabkinesin-6 antibody did not inhibit the
targeting of GST–Rab6A to the Golgi (Fig. 5C).
Several factors have recently been correlated to Rab6-dependent
retrograde transport from the Golgi to the ER, including the ER
SNARE syntaxin 18 and its putative tether complex RINT-1 and
ZW10 [50–52]. Because SNARE syntaxin 18 is a transmembrane pro-
tein [53], the protein should be absent in the (L5178Y) cytosol.
Therefore, it is unlikely that SNARE syntaxin 18 would be involved
in the cytosol-dependent Golgi targeting of Rab6A (see Fig. 1C and D).
Therefore, we examined whether the tether complex RINT-1 and
ZW10 played a role in Rab6A targeting. We performed the Golgi-
targeting assay using anti-ZW10 antibody. Semi-intact HeLa cells were
incubated at 32 °C for 30 min with control rabbit IgG or anti-ZW10 an-
tibody in the presence of GST–Rab6A, an ATP-regenerating system, and
3 mg/ml HeLa S3 cytosol. In the subsequent Golgi-targeting assay, anti-
ZW10 antibody did not inhibit the targeting of GST–Rab6A to the Golgi
(Fig. 5D). We also found that ZW10 did not speciﬁcally bind to Rab6A
(Supplementary Fig. 4D). These results indicate that the RINT-1 and
ZW10 complex was not involved in the targeting of Rab6A.
Taken together with the results in the Golgi-targeting assay in the
presence of antibodies, these data may suggest that human cytosolic
BICD2, but not BICD1, Rabkinesin-6, nor RINT-1/ZW10, speciﬁcally
mediates the targeting of GST–Rab6A in semi-intact HeLa cells.
In Golgi-targeting assays, Cytosol (−RBP) inhibited the targeting
of GST–Rab6A to the Golgi (Fig. 3C), probably because of the lack of
BICD2. Thus, a recombinant BICD2 protein was added to Cytosol
(−RBP) to examine whether it could restore normal targeting. In
these experiments, cloning of the human BICD2 gene from a human
cDNA library was unsuccessful and a His-tagged mouse BICD2 pro-
tein (referred to as His-mBICD2), which is highly homologous to
human BICD2 (approximately 95%), was prepared using an E. coli
system. After incubation of semi-intact HeLa cells with Cytosol
(−RBP), GST–Rab6A, and an ATP-regenerating system in the pres-
ence or absence of His-mBICD2 at 32 °C for 30 min, Golgi-targeting
assays showed restoration of GST–Rab6A targeting to the Golgi
(1.26 ± 0.07) following addition of His-mBICD2 to Cytosol (−RBP;
Fig. 5E). Taken together with the results of previous experiments,
these data suggest that both human and mouse BICD2 facilitate the
targeting of GST–Rab6A to the Golgi.
3.6. Slowed dynamics of GFP–Rab6A inHeLa cells expressing the C-terminal
region of BICD2
The effects of BICD2 on dynamic interactions between Rab6A and
the Golgi were investigated using FRAP analysis. Because BICD2 report-
edly interacts with Rab6 via its C-terminal region [44,54], we construct-
ed an mCherry-tagged C-terminal fragment of mouse BICD2 (amino
acids 706–810, BICD2706–810) (mCherry–BICD2706–810) and a truncated
mutant of mouse BICD2 lacking the C-terminal region (mCherry–
BICD21–705; Fig. 6A). Subsequent coimmunoprecipitation and immuno-
ﬂuorescence analyses conﬁrmed that mCherry–BICD2706–810 interacts
with GFP-tagged Rab6A (GFP–Rab6A), mainly at the Golgi (Fig. 6B and
C). Although coimmunoprecipitation analysis indicated an interaction
of mCherry–BICD21–705 and GFP–Rab6A (Fig. 6B), immunoﬂuorescenceinal region of BICD2. A. Domain structures of mouse BICD2 protein and its truncated forms
oxes). B. Coimmunoprecipitation of GFP–Rab6A and either mCherry-tagged BICD2706–810
re cotransfected with plasmids expressing GFP–Rab6A and either mCherry–BICD2706–810
y or control rabbit IgG. Immunoprecipitates were analyzed using western blotting (WB)
periments. C. Immunoﬂuorescence analysis of HeLa cells expressing GFP–Rab6A and the
g GFP–Rab6A andmCherry–BICD2706–810, mCherry–BICD21–705, or empty mCherry vector
The dynamics of GFP–Rab6A between the Golgi and other cellular regions in HeLa cells
d mCherry–BICD2706–810, mCherry–BICD21–705, or empty mCherry vector as a control
representative images of GFP–Rab6A at indicated time points. Bars: 20 μm. Results are
errors (n = 3–5 cells per experiment).
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BICD21–705 at the Golgi (Fig. 6C).
In further experiments, HeLa cells were cotransfected with GFP–
Rab6A and either mCherry–BICD2706–810 or mCherry–BICD21–705, and
immunoﬂuorescence staining with an anti-p230 antibody revealed pre-
dominant colocalization of GFP–Rab6A and p230 in both cell types. How-
ever, the Golgi appeared to be slightly fragmented in GFP–Rab6A and
mCherry–BICD21–705-cotransfected cells (Fig. 6C). Subsequently, the
cotransfected cells were subjected to FRAP analysis using cells that
were cotransfected with GFP–Rab6A and empty mCherry vector
(mock) as a control. In these experiments, ﬂuorescence recovery curves
of GFP–Rab6A corresponded approximately with the exchange rate of
GFP–Rab6A between the cytosol and Golgi membranes. Moreover, the
recovery curves in mCherry–BICD21–705-expressing cells were rarely dif-
ferent from those in empty mCherry-expressing cells (mock; Fig. 6D). In
contrast, the recovery curves in mCherry–BICD2706–810-expressing cells
were considerably slower than those in the control (Fig. 6D). These ob-
servations suggest that the C-terminal region of BICD2 (BICD2706–810)
binds Golgi-localized GFP–Rab6A tightly, and competitively inhibits the
exchange between cytosolic and Golgi-associated GFP–Rab6A, resulting
in decreased exchange of GFP–Rab6A between the cytosol and Golgi
membranes. Accordingly, the C-terminal region of BICD2 may facilitate
the stabilization of Golgi membrane-bound GFP–Rab6A.
3.7. Stabilization of the GTP-bound form of Rab6 at the Golgi by BICD2 but
not BICD1
To determine whether BICD2 stabilizes Rab6 in its GTP-bound active
form, the amounts of active GTP-bound Rab6 (Rab6-GTP) in BICD1-
and/or BICD2-knockdown cellswere determined. According to the report
of Nizak et al. [55], we used an antibody that speciﬁcally recognizes both
Rab6A-GTP and Rab6A′-GTP. Although unsuccessful in western blotting
analyses, the anti-Rab6-GTP antibody showed sufﬁcient reactivity in im-
munoﬂuorescence staining experiments. HeLa cells were transfected
with control (scramble), BICD1, and/or BICD2 siRNA, and after 72 h, the
cells were ﬁxed and triple-stained with antibodies against Rab6-GTP,
Rab6, and p230. The ﬂuorescence intensity of Rab6-GTP was decreased
in BICD2-knockdown cells (transfected with BICD2 siRNA #1, BICD2
siRNA #2, or BICD1 + 2 siRNA) compared with that in control cells
(transfected with scramble siRNA; Fig. 7A). As shown in Fig. 4A and Sup-
plementary Fig. 6E and F,western blotting analyses conﬁrmed that BICD1
and/or BICD2 knockdown did not affect the expression of total Rab6 (in-
cluding both GTP-bound and GDP-bound forms). Therefore, to examine
the changes in the ratio of Rab6-GTP to total Rab6, wemeasured the ﬂuo-
rescence intensities of Rab6-GTP andRab6 in the entire region of cells and
investigated the ﬂuorescence intensity ratio (Rab6-GTP/Rab6) after
transfection with each siRNA. Whereas BICD2 knockdown (BICD2
siRNA#1, BICD2 siRNA#2, and BICD1+2 siRNA) reduced this ratio com-
pared with the control (scramble siRNA; Fig. 7B), BICD1 knockdown
(BICD1 siRNA #1 and BICD1 siRNA #2) had no effect, suggesting that
only BICD2 stabilizes the GTP-bound form of Rab6.
3.8. Delayed Golgi-derived tubule fusion with the ER in BICD2-knockdown
BFA-treated HeLa cells
To investigate the role of BICD2 on the function of Rab6A, we con-
sidered vesicular transport mediated by Rab6A, which has been
shown to be involved in COPI-independent retrograde transport from
the Golgi to the ER [17,18,20]. BICD2 also has a reported role in COPI-Fig. 7. Immunoﬂuorescence analysis of BICD1-, BICD2-, and BICD1/BICD2-knockdown HeLa ce
siRNA #2, BICD2 siRNA #1, BICD2 siRNA #2, or both BICD1 #2 and BICD2 #2 siRNAs (BICD1 +
and the trans-Golgi and TGN marker p230. Bars: 20 μm. B. A box plot showing the ﬂuorescenc
lines within boxes represent medians; whiskers indicate 0th and 100th percentiles. Results are
siRNA was arbitrarily assigned as 1. n = 30 cells. ***P b 0.001 compared with control siRNA coindependent retrograde transport [44]. Thus, we investigated retro-
grade transport from the Golgi to the ER using GT–GFP in BFA-treated
cells. Because GT is a transmembrane Golgi-resident enzyme and GT–
GFP is recycled between the Golgi and the ER, we used GT–GFP as a
probe for morphological changes in the Golgi during mitosis or as a
cargo probe for antero- or retrograde vesicular transport between the
Golgi and the ER [28,33,56,57]. For subsequent retrograde transport as-
says, HeLa cells were transfected with scramble (control), Rab6, or
BICD2 #2 siRNA and incubated at 37 °C for 48 h. After incubation, the
cells were transfected with a plasmid encoding GT–GFP and incubated
again at 37 °C for 24 h. The cells were then treated with 10 μg/ml BFA
for 0–30 min, ﬁxed, and observed using an LSM510 confocal micro-
scope. Morphological changes in the Golgi occurred gradually with in-
cubation times and with BFA-induced Golgi disassembly processes,
including Golgi tubule formation and Golgi tubule fusion (with the ER;
see Fig. 8A). To investigate the kinetics of BFA-induced Golgi disas-
sembly, the numbers of cells with intact Golgi (Golgi), numbers of in-
tact Golgi and Golgi tubules (Golgi + tubules), and numbers of Golgi
tubules and ER (tubules + ER) or ER networks (ER) were counted at
each incubation time, and the ratios of cell types were calculated. The
reduction of Rab6 or BICD2 was conﬁrmed by western blotting (72 h
after siRNA transfection; Fig. 8B). As shown in Fig. 8C, “Golgi” ratios
in Rab6-knockdown, BICD2-knockdown, and control cells decreased
to 0%within 30min of incubation. However, the kinetics of decreases
in Rab6- or BICD2-knockdown cells were slightly delayed compared
with those in control cells. Moreover, the ratios of “Golgi + tubules”
increased transiently for 10 min and then decreased to 0% after
30 min in Rab6- and BICD2-knockdown cells, and this was slightly
delayed in comparison with that in control cells. These data indicate
that BICD2 and Rab6 are involved in Golgi tubule formation, al-
though with limited effects.
In contrast with Golgi tubule formation, Golgi tubule fusion to the ER
was markedly affected by Rab6 or BICD2 knockdown (Fig. 8C). Ac-
cordingly, the ratios of “tubules + ER” and “ER” in Rab6- and BICD2-
knockdown cells were evidently different from those in control cells
(Fig. 8C), suggesting that Rab6 and BICD2 inhibit the membrane fusion
process between Golgi tubules and ER membranes. Furthermore, the
kinetics of Golgi tubule formation and Golgi tubule fusion were similar
in Rab6- and BICD2-knockdown cells (Fig. 8C), suggesting codependent
functional redundancy of these proteins.
In further experiments, the effects of Rab6- and BICD2-knockdown
on retrograde transport from plasma membranes to the ER via the
Golgi were investigated using Alexa Fluor 488-labeled Shiga toxin 1
(Stx1), which is reportedly transported by the COPI-independent path-
way. Transport assayswere not possible under these conditions because
of marked decreases in the binding of Stx1 to plasma membranes in
BICD2-knockdown cells compared with that in control cells (Matsuto
and Murata, unpublished data). However, other retrograde vesicular
transport pathways were investigated using the Alexa Fluor 488-
labeled cholera toxin B subunit (CtxB), which is transported by the
COPI-dependent pathway. The transport kinetics in Rab6- and BICD2-
knockdown cells were indistinguishable from those in control cells
(Supplementary Fig. 7A and B). Subsequently, we investigated an-
terograde vesicular transport from the ER to the plasma membranes
via the Golgi using VSVGts045-GFP. In these experiments, BICD2
knockdown had no effect on the kinetics of transport, although Rab6
knockdown slightly delayed the kinetics from theGolgi to plasmamem-
branes (Supplementary Fig. 8). In subsequent experiments, we in-
vestigated the transport between endosomes and the TGN usinglls. A. HeLa cells were transfected with control (scramble) siRNA, BICD1 siRNA #1, BICD1
2). After 72 h, the cells were ﬁxed and stained with antibodies against Rab6-GTP, Rab6,
e intensity ratio of Rab6-GTP to Rab6. Boxes show 25th and 75th percentiles; horizontal
representative of 2 independent experiments. The mean ratio in the presence of control
ndition (Steel's test).
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Fig. 8.Transport assay forGT inBFA-treatedRab6- or BICD2-knockdownHeLa cells. HeLa cellswere transfectedwith control (scramble), Rab6, or BICD2#2 siRNAand incubated at 37 °C for
48 h. After incubation, the cells were transfectedwith a plasmid encoding GT–GFP andwere further incubated at 37 °C. After incubation for 24 h, the cells were treatedwith 10 μg/ml BFA
for the indicated times, ﬁxed, and observed using an LSM510 confocal microscope (Carl Zeiss). The kinetics of the BFA-induced Golgi disassembly process were analyzed by dividing the
transport process into 4 stages as follows: Golgi, GT–GFP is localized to perinuclear regions typical of theGolgi; Golgi+ tubules, tubules emerge from theperinuclear regions; tubules+ER,
tubules fuse with the ER (cytoplasmic reticular structures are visualized using GT–GFP) and tight perinuclear staining disappears; ER, GT–GFP is redistributed to ER networks and tubules
completely disappear. A. Representative images of each stage of BFA-treated HeLa cells are presented. Bars: 20 μm. B. HeLa cells were transfected with control (scramble), Rab6, or BICD2
#2 siRNA. After 72 h, the cells were lysed and subjected to western blotting to determine the knockdown efﬁciency of the siRNAs; GAPDH was used as a loading control. This ﬁgure is
representative of 3 independent experiments. C. Kinetics of Golgi disassembly processes in BFA- and siRNA-treated cells. The graph shows the mean and standard deviation percentages
of cells in which GT–GFP was observed at each stage. Data are presented as means and standard deviations of 3 independent experiments (n = 100 cells per experiment).
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independentmannose-6-phosphate receptor (CI-M6PR) [58]. These ex-
periments showed diminished colocalization of CI-M6PR with p230 in
Rab6-knockdown cells but no changes in BICD2-knockdown cells (Sup-
plementary Fig. 9).
Collectively, these results suggest that BICD2 and Rab6 are inter-
dependently involved in retrograde transport from the Golgi to the ER,
particularly during the fusion step between Golgi-derived vesicles and
ER membranes.4. Discussion
In this study, we established a reconstitution system for the
targeting of Rab6A protein to the Golgi apparatus in a cytosol-
dependent manner. Using this system in semi-intact HeLa cells, we
investigated the biochemical requirements of targeting from the cy-
tosol, isolated cytosolic factors that may mediate Rab6A targeting,
and identiﬁed BICD2 as a primary candidate. Because no speciﬁc
anti-BICD1 or 2 antibody was available for immunodepletion of
2607M. Matsuto et al. / Biochimica et Biophysica Acta 1853 (2015) 2592–2609BICD1 or 2 from the cytosol, Golgi-targeting assays were not possible
using BICD1- or 2-depleted cytosols. Thus, assays were performed
using cytosols containing antibodies against BICD1 or 2, and the ef-
fects of added antibodies on the Golgi targeting of GST–Rab6A were
examined. In these experiments, exogenous anti-BICD2 antibody
inhibited Golgi targeting, whereas anti-BICD1 antibody did not
(Fig. 5A and B). We also performed a Golgi-targeting assay in the
presence of cytosol containing anti-Rabkinesin-6 antibody. Because
Rabkinesin-6 is a known Rab6A-binding protein [43,49], we consider
that this protein is an obvious candidate regulator of Rab6A tar-
geting. However, in this experiment, anti-Rabkinesin-6 antibody
did not inhibit the targeting of GST–Rab6A to the Golgi (Fig. 5C). Al-
though we could not exclude the possibility that the anti-BICD1,
anti-Rabkinesin-6 and anti-ZW10 (discussed below) antibodies did
not react in the Golgi-targeting assay (Fig. 5B, C and D), the results
in Fig. 5 together suggest that BICD2 mediates the targeting of
GST–Rab6A to the Golgi in semi-intact HeLa cells, because restora-
tion of GST–Rab6A targeting to the Golgi was observed when semi-
intact HeLa cells were incubated in the presence of recombinant
BICD2 protein (Fig. 5E). In addition, cell fractionation experiments
demonstrated small but signiﬁcant amounts of Rab6 in the mem-
brane fractions (mainly associated with the Golgi membranes).
Although these were decreased in BICD2-knockdown cells in com-
parison with control cells (Fig. 4D and E), they were not decreased
in BICD1-knockdown cells (Supplementary Fig. 6C and D). Collec-
tively, the present Golgi-targeting assays allowed identiﬁcation of
the cytosolic protein BICD2 as a candidate of Rab6A targeting to the
Golgi.
Rab proteins must be prenylated for insertion into membranes
[38–40]. As shown in Supplementary Fig. 2A, GST–Rab6A was
prenylated after incubation with semi-intact HeLa cells in the pres-
ence of L5178Y cytosol, although the efﬁciency of prenylation was
relatively low. We believe that the interpretations of these results
are appropriate because the efﬁciency of prenylation seems to
differ among cell types, Rab proteins, and expression levels (i.e.,
endogenous or overexpressed) of the Rab protein [5,59–62]. Re-
garding bacterially expressed Rab proteins, our results are in accor-
dance with those of previous reports [63,64]. Additionally, in the
present study, GST–Rab6A was incubated in the presence of
L5178Y cytosol without the addition of geranylgeranyl pyrophos-
phate (GGPP) as a prenyl group donor. The absence of exogenously
added GGPP can result in the incomplete prenylation of GST–Rab6A
[62,64–66]. The unprenylated GST–Rab6A may be distributed in
cellular regions other than the Golgi apparatus in semi-intact
HeLa cells. Alternatively, we cannot completely exclude the possi-
bility that the Golgi-targeting assay could detect a prenylation-
dependent indirect association of GST–Rab6A with the Golgi
membranes.
The Rab6 effector BICDwas ﬁrst identiﬁed in Drosophila [46,47] as
a cytoplasmic protein, with several highly conserved coiled-coil do-
mains from Caenorhabditis elegans to mammals. In Drosophila, BICD
plays an essential role in dynein-mediated transport of mRNAs dur-
ing oogenesis and embryogenesis [47,67]. The 2 mammalian homo-
logues BICD1 and BICD2 [45] have high homology; they may
compensate for each other's function [48] and are reportedly distrib-
uted in the cytoplasm, TGN, vesicle-like structures, and centrosomes
[44,45,48]. Both colocalize with Rab6A to the Golgi and to vesicle-
like structures in the cytoplasm [44] and both bind wild-type Rab6
and the GTP-restricted mutant Rab6Q72L but not the GDP-bound
mutant Rab6T27N [68]. In addition, BICD2 directly binds Rab6 and
dynamitin (p50), which is a subunit of dynactin complexes that
mediate dynein-dependent Golgi-to-ER transport of Rab6-positive
vesicles [44,45,68]. In the present study, BICD2 was involved in the
targeting (especially the binding) of Rab6A to the Golgi, whereas
BICD1 was not (Fig. 5 and see Figs. 4 and 7 and Supplementary
Fig. 6). Although a previous study suggests that BICD1 and BICD2have compensatory functions [48], the present data suggest a greater
dependence of Rab6A–Golgi binding on BICD2 than on BICD1.
4.1. Stabilization of the Golgi binding of Rab6A by BICD2
Rab effectors, such as BICD1 and BICD2, are generally recruited to a
speciﬁc organelle membrane via interactions with Rab proteins [1,69,
70]. A previous study reported Rab6-dependent binding of BICD2 to
the Golgi membranes [44]. In contrast, the present data demonstrate a
role for BICD2 in the Golgi targeting of Rab6A (Fig. 5E). To examine
this inconsistency, we investigated the effects of Rab6 knockdown on
the amounts of Golgi-associated BICD2. We performed subcellular frac-
tionation experiments to determine whether BICD2 was decreased in
the membrane fractions. However, because almost all BICD2 protein
was present in the cytosol fractions (approximately 90% in scramble
siRNA-transfected cells), no signiﬁcant changes in membrane (Golgi)-
bound BICD2 were detectable in Rab6-knockdown cells (Supplementa-
ry Fig. 5A). Because the present anti-BICD2 antibodywas not suitable for
immunoﬂuorescence staining,we next performed immunoﬂuorescence
analysis of GFP-tagged mouse BICD2 (referred to as GFP-mBICD2)-
expressing control and Rab6-depleted HeLa cells and quantiﬁed the
amount of GFP-mBICD2 present on the Golgi (p230 was used as the
Golgi marker). The results suggest that the GFP-mBICD2 signal in the
Golgi was decreased in Rab6-depleted cells (Supplementary Fig. 5B
and C). Therefore, the present data indicate the Rab6-dependent Golgi
targeting of BICD2 as previously reported [44] and suggest that Rab6
functions in BICD2 targeting and BICD2 stabilizes Rab6A on Golgi mem-
branes. In agreement, the Rab9 effector TIP47 was previously shown to
regulate the localization and stability of Rab9 in late endosomes [14,15].
Similarly, BICD2 may regulate the binding and stable localization of
Rab6A to the Golgi membranes.
Although the cytosolic factor BICD2 is reportedly involved in dynein-
dependent Golgi-to-ER transport of Rab6-positive vesicles [44,45,68],
we demonstrated that the cytosol-dependent Golgi targeting of Rab6A
was independent of microtubules. We also found that overexpression
of the C-terminal region of BICD2 (BICD2706–810) slowed the exchange
rate of GFP–Rab6A between the Golgi and the cytoplasm compared
with that in control cells. In contrast, overexpression of BICD2 contain-
ing the N-terminal region (BICD21–705) did not affect the exchange
rate or localization of GFP–Rab6A. The N-terminal domain of BICD2
reportedly interacts with dynein–dynactin complexes [45]. Thus, the
present results indicate that the C-terminal region of BICD2 regulates
the targeting of Rab6A to the Golgi in a microtubule-independent man-
ner. As shown in Fig. 6B, coimmunoprecipitation analysis indicated an
interaction of mCherry–BICD21–705 and GFP–Rab6A. In contrast, immu-
noﬂuorescence analysis showed almost no colocalization of GFP–Rab6A
with mCherry–BICD21–705 at the Golgi (Fig. 6C). Previous studies have
demonstrated that BICD2 directly interacts with Rab6A via its C-
terminal region [44,54,71] but not the N-terminal region [71]. The N-
terminal domain of BICD2 reportedly interacts with dynein–dynactin
complexes [45,72] or with BICD2 itself [45]. Furthermore, several
studies have reported that Rab6A interacts with subunits of the
dynein–dynactin complexes [54,68,71,73]. Taking these reports into ac-
count, the interaction between mCherry–BICD21–705 and GFP–Rab6A
(Fig. 6B) may be indirect through the interactions of endogenous
BICD2 and/or dynein–dynactin complexes in the cytoplasm. Therefore,
it does not affect the conclusion that the C-terminal region of BICD2
may facilitate stabilization of Golgi membrane-bound GFP–Rab6A.
Potentially, BICD2-dependent Rab6A targeting to the Golgi may re-
ﬂect the stabilization of Rab6A binding and activation in the Golgimem-
branes following the inhibition of GTP hydrolysis. In agreement, in vitro
experiments showed that the interaction of Rab6A with the C-terminal
domain of BICD2 inhibited the intrinsic GTPase activity of Rab6A [54].
Furthermore, several studies have reported Rab effectors that inhibit
GTP hydrolysis activities of Rab proteins [74–77]. Considering these re-
ports, our results suggest that BICD2acts as an effector for Rab6 andmay
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of GTP hydrolysis can lead to increased GTP-bound membrane-
associated Rab6, the results in Fig. 7 may support those in Fig. 4.
Alternatively, BICD2may act as a GEF for Rab6A. However, in in vitro
GEF assays using recombinant Rab6A and BICD2 proteins, no signiﬁcant
GEF activity was detected (Supplementary Fig. 10).
Taken together, these data indicate a BICD2-mediated mechanism
for Rab6A targeting to the Golgi. Accordingly, interactions of Rab6A
and BICD2 inhibit GTP hydrolysis activity of Rab6A in vivo and in vitro
[54], leading to the inhibition of Rab6A inactivation and stabilization
of Rab6A binding to the Golgi membranes.
4.2. The role of BICD2 in Golgi-to-ER retrograde transport
As shown in Supplementary Fig. 8, anterograde transport of
VSVGts045-GFP from the ER to the Golgi occurred normally in both
Rab6- and BICD2-knockdown cells, although the transport of
VSVGts045-GFP from the Golgi to plasma membranes was slightly
delayed in Rab6-knockdown cells. However, retrograde transport
of GT–GFP from the Golgi to the ER was delayed in BFA-treated
Rab6- and BICD2-knockdown cells, particularly during fusion of
Golgi-derived tubules with the ER (Fig. 8C). Rab6A is reportedly in-
volved in COPI-independent retrograde transport from the Golgi to
the ER, and BICD2 has been implicated in Rab6-dependent Golgi-
to-ER retrograde transport [17,18,20,44]. Thus, BICD2 and Rab6A
may be involved in the fusion of transport vesicles and the ER in
COPI-independent retrograde transport. Collectively, the present
data are consistent with the ﬁndings of Matanis et al. [44] and further
suggest that BICD2 modulates the function of Rab6A by regulating its
Golgi targeting.
During membrane transport between organelles, tethering com-
plexes are reportedly related to vesicle docking, and soluble N-
ethylmaleimide-sensitive factor attachment protein receptors
(SNARE) are involved in vesicle fusion [78]. Recently, several factors
have been related to vesicle docking and fusion during Rab6-
dependent retrograde transport from the Golgi to the ER, including
the ER SNARE syntaxin 18 and putative tether complex RINT-1 and
ZW10 [50–52]. Therefore, we performed the Golgi-targeting assay
in the presence of cytosol containing anti-ZW10 antibody to explore
whether ZW10 played a role in Rab6A targeting (Fig. 5D). In this ex-
periment, anti-ZW10 antibody did not inhibit the targeting of GST–
Rab6A to the Golgi in semi-intact HeLa cells. Sun et al. [52] suggested
that Rab6 and BICD2 function in a retrograde transport pathwaywith
the ZW10/RINT-1 complex. Although our analyses of the retrograde
transport of GT–GFP in BFA-treated cells may reﬂect the actions of
the same systems, further experiments are required to characterize
the related mechanisms.
The present semi-intact cell assay is suitable for investigating the
biochemical requirements of processes involving maintenance of or-
ganelle integrity and conﬁguration. In the present study, we used this
system to reconstitute Rab6A targeting to the Golgi and identiﬁed
BICD2 as a regulating factor. This targeting assay is broadly applicable
to investigations of the biochemical requirements of the targeting of
many proteins, including other Rab proteins, to their speciﬁc organelles.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.05.005.
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